Publications

Add filters (0)

11 results

A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis.

January 1, 2023

Aliment Pharmacol Ther

Abstract BACKGROUND Primary sclerosing cholangitis (PSC) is a progressive bile duct disease associated with inflammatory bowel disease (PSC-IBD). AIM To investigate whether patients with PSC-IBD benefit from a gluten-free and amylase trypsin inhibitor (ATI)-free diet (GFD). METHODS We performed a prospective clinical pilot study administering an eight-week GFD. The primary outcomes were colonic inflammation assessed […]

Read publication

Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn’s disease.

August 1, 2022

Aliment Pharmacol Ther

Abstract BACKGROUND Increased collagen remodelling is a key pathophysiological component underlying intestinal stricture and fistula development in Crohn’s disease (CD). AIMS To investigate associations between serological biomarkers of collagen turnover and disease behaviour according to the Montreal classification in patients with CD. METHODS Serological biomarkers of type III/IV collagen formation (PRO-C3, PRO-C4) and matrix metalloproteinase […]

Read publication

Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation.

October 1, 2021

Aliment Pharmacol Ther

Abstract BACKGROUND Liver fibrosis accumulation is considered a turnover disease, with formation exceeding degradation, although this hypothesis has never been tested in humans. AIMS To investigate extracellular matrix (ECM) remodelling in a biopsy-controlled study of alcohol-related liver disease (ALD) patients. METHODS We evaluated the relationship between formation and degradation of four collagens as a function […]

Read publication

PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease.

September 1, 2021

Aliment Pharmacol Ther

Abstract BACKGROUND Alcohol is a main cause of preventable deaths and frequently leads to the development of alcohol-related liver disease. Due to the lack of diagnostics, patients are commonly diagnosed after developing clinical manifestations. Recently, the biomarker PRO-C3 was shown to accurately identify fibrosis due to non-alcoholic fatty liver disease. AIM To assess the diagnostic […]

Read publication

Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis.

July 1, 2020

Aliment Pharmacol Ther

Abstract BACKGROUND Patients with liver fibrosis show a large heterogeneity, and for that reason effective treatments are still lacking. Emerging data suggest that there is more to fibrosis than previously understood. Opposed to earlier belief of being a passive scaffold for cells to reside in, the extracellular matrix (ECM) is now known to hold both […]

Read publication

Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program.

October 1, 2019

Aliment Pharmacol Ther

Abstract BACKGROUND Lifestyle modifications remain the cornerstone of treatment in non-alcoholic fatty liver disease (NAFLD). However, they requently fail related to the inability of patients to implement lasting changes. AIMS To evaluate the effects of a short, web-based, individualised exercise program on non-invasive markers of hepatic steatosis, inflammation and fibrosis. METHODS Patients with histologically confirmed […]

Read publication

Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease.

July 1, 2017

Aliment Pharmacol Ther

Abstract BACKGROUND Misbalances in extracellular matrix turnover are key factors in the development of stricturing (Montreal B2) and penetrating (Montreal B3) Crohn’s disease. AIM To determine whether serological markers for collagen formation and degradation could serve as biomarkers for complications of Crohn’s disease. METHODS Serum biomarkers for type I, III, V and VI collagen formation […]

Read publication

Fibrosis is not just fibrosis – basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury.

December 1, 2016

Aliment Pharmacol Ther

Abstract BACKGROUND While morphological patterns differ, the molecular phenotype of liver fibrosis is considered a stereotypical response to chronic liver injury. However, with different cellular triggers and networks regulating fibrosis, the molecular responses of the injured liver may not be identical. AIM To investigate whether differences in extracellular matrix (ECM) composition of the liver during […]

Read publication

Review article: the efficacy of biomarkers in chronic fibroproliferative diseases – early diagnosis and prognosis, with liver fibrosis as an exemplar.

August 1, 2014

Aliment Pharmacol Ther

Abstract BACKGROUND Nearly 45% of all deaths are associated with chronic fibroproliferative diseases, of which the primary characteristic is altered remodelling of the extracellular matrix. A major difficulty in developing anti-fibrotic therapies is the lack of accurate and established techniques to estimate dynamics of fibrosis, regression or progression, in response to therapy. AIM One of […]

Read publication